Based on organ specificity, many molecular assays have been developed for monitoring organ pathological states and disease progression, such as the cardiac trophonin (cTn) test for the heart [1], alanine transaminase (ALT) and aspartate transaminase (AST) tests for the liver [2], and prostate-specific membrane antigen (PSMA) for prostate cancer [3]. This evidence concerns the gene FOLH1 and prostate cancer.